Indap 2,5 mg capsules 30

Size chart
Women's clothing size
Euro 32/34 36 38 40
USA 0/2 4 6 8
Bust(in) 31-32 33 34 36
Bust(cm) 80.5-82.5 84.5 87 92
Waist(in) 24-25 26 27 29
Waist(cm) 62.5-64.5 66.5 69 74
Hips(in) 34-35 36 37 39
Hips(cm) 87.5-89.5 91.5 94 99
How To Measure Your Bust

With your arms relaxed at your sides, measure around the fullest part of your chest.

How To Measure Your Waist

Measure around the narrowest part of your natural waist, generally around the belly button. To ensure a comfortable fit, keep one finger between the measuring tape and your body.

Volume discounts

Quantity Unit discount You Save
2 33% $13.40
3 38% $23.14
4 46% $37.35
 Customer ratings and reviews
Nobody has posted a review yet
in this language
Add to compare0
Add to wishlist
Active ingredient

Active substance: indapamide 2.5 mg.

Excipients: microcrystalline cellulose (granular), lactose monohydrate, corn starch, magnesium stearate, silicon dioxide colloidal, titanium dioxide, gelatin, dye indigocarmine.

Pharmacological properties

Antihypertensive drug, diuretic.

Indapamide belongs to the group of non-thiazide sulfonamides, in pharmacological properties it is close to thiazide-like diuretics. Reduces the tone of the smooth muscles of the arteries, reduces OPSS. The drug has moderate saluretic and diuretic effects, which are associated with the blockade of the reabsorption of sodium, chlorine, hydrogen and, to a lesser extent, potassium ions in the proximal tubules and cortical segment of the distal tubules of the kidneys. Having the ability to selectively block slow calcium channels, it increases the elasticity of the walls of the arteries and reduces OPSS. Helps to reduce hypertrophy of the left ventricle of the heart. Does not affect the content of lipids in the plasma (triglycerides, LDL, HDL); does not affect carbohydrate metabolism (including in patients with concomitant diabetes mellitus). The decrease in OPSS is also due to a decrease in the sensitivity of adrenergic receptors of the vascular wall to norepinephrine and angiotensin II, an increase in the synthesis of prostaglandins with vasodilating activity (prostaglandin PgE2 and prostacyclin PgI2). Reduces the production of free and stable oxygen radicals. When administered in high doses, it does not affect the degree of decrease in blood pressure, despite the increase in diuresis.

The antihypertensive effect is manifested by the end of the first week, persists for 24 hours against the background of a single dose, reaches a maximum 8-12 weeks after the start of taking the drug.

Indications for use
Arterial hypertension.
  • hypersensitivity to indapamide, other sulfonamide derivatives and components of the drug;
  • acute violation of cerebral circulation;
  • severe hepatic (including with encephalopathy) and / or renal failure, anuria;
  • hypokalemia;
  • simultaneous administration of drugs that prolong the QT interval;
  • lactose intolerance, galactosemia, glucose absorption syndrome, galactose;
  • pregnancy;
  • lactation (breastfeeding);
  • age up to 18 years (efficacy and safety have not been established).

With caution: diabetes mellitus in the stage of decompensation, hyperuricemia (especially accompanied by gout and urate nephrolithiasis), hyponatremia and other disorders of water-electrolyte metabolism, moderate hepatic and / or renal failure, ascites, coronary artery disease, chronic heart failure, prolongation of the QT interval; Hyperparathyroidism.

Use in pregnancy and lactation

Indap ® contraindicated for use during pregnancy and lactation (breastfeeding).

Use in case of impaired liver function

Contraindicated in severe violations of liver function. With caution in moderate liver failure.

Use in renal dysfunction

Contraindicated in severe renal dysfunction, anuria. With caution in moderate renal failure.

Use in children
Contraindicated in children under 18 years of age
Use in elderly patients
In the elderly, careful monitoring of potassium content and Creatinine.
Special instructions

Indapamide is effective for the treatment of patients with arterial hypertension of the risk group, i.e. with concomitant pathology (diabetes mellitus of mild and moderate severity or with chronic renal failure, patients with hyperlipidemia).

With prolonged use of indapamide, electrolyte metabolism disorders can sometimes occur, such as hyponatremia, hypokalemia, hypercalcemia and hypochloremic alkalosis. These disorders are more often observed in patients with chronic heart failure, liver disease, vomiting and diarrhea, as well as in persons on a salt-free diet, which necessitates the control of blood electrolytes.

Indapamide increases the excretion of magnesium in the urine, which can lead to hypomagnesemia.

When using indapamide, the content of uric acid and residual nitrogen in the blood plasma should also be systematically monitored.

It's possible the appearance of orthostatic hypotension, which can be provoked by alcohol intake, barbiturates, opioid analgesics, as well as other antihypertensive drugs.

In the case of hypokalemia caused by indapamide, the toxicity of cardiac glycosides may increase. In patients taking cardiac glycosides, laxatives, with hyperaldosteronism, as well as in the elderly, careful monitoring of the content of potassium and creatinine is indicated.

The most careful monitoring is indicated in patients with cirrhosis of the liver (especially with edema or ascites - the risk of developing metabolic alkalosis, which increases the manifestations of hepatic encephalopathy), coronary artery disease, chronic heart failure, as well as in the elderly. The high-risk group also includes patients with an increased QT interval on the ECG (congenital or developed against the background of any pathological process).

The first measurement of the concentration of potassium in the blood should be carried out in within 1 week of treatment.

Hypercalcemia while taking indapamide may be a consequence of previously undiagnosed hyperparathyroidism.

In patients with diabetes mellitus, it is extremely important to control the level of glucose in the blood, especially in the presence of hypokalemia.

Significant dehydration can lead to the development of acute renal failure (decreased glomerular filtration). Patients need to compensate for the loss of water and carefully monitor kidney function at the beginning of treatment.

Indapamide can give a positive result during doping control.

Patients with arterial hypertension and hyponatremia (due to taking diuretics) should stop taking diuretics 3 days before the start of taking ACE inhibitors (if necessary, diuretics can be resumed a little later), or they are prescribed initial low doses of ACE inhibitors.

Indapamide may worsen the course of systemic red Lupus.

Despite the fact that indapamide practically does not affect carbohydrate metabolism, in patients with insulin-dependent diabetes mellitus, it is possible to increase the required dose of insulin, and with latent diabetes mellitus, it is necessary to monitor blood glucose.

Dosage and Administration

The drug is prescribed orally, in the morning, regardless of food intake. The capsule should be swallowed without chewing, washed down with water.

Assign 2.5 mg (1 caps.) 1 time / day.

The drug can be used as monotherapy or in combination with other antihypertensive drugs (with beta-blockers, blockers of "slow" calcium channels, ACE inhibitors). If after 4-8 weeks of treatment the desired therapeutic effect is not achieved, the dose of the drug is not recommended to be increased (the risk of side effects increases without enhancing the antihypertensive effect). Instead, it is advisable to add another one to the treatment regimen. antihypertensive drug that is not a diuretic. In cases where treatment should begin with taking 2 drugs, the dose of the drug Indap ® remains equal to 2.5 mg in the morning 1 time / day.


Symptoms: nausea, vomiting, weakness, impaired gastrointestinal function, water-electrolyte disorders, in some cases - excessive decrease in blood pressure, respiratory depression. In patients with cirrhosis of the liver, the development of hepatic coma is possible.

Treatment: gastric lavage, correction of water-electrolyte balance, symptomatic therapy. There is no specific antidote.

Side effects

From the digestive system: nausea, vomiting, anorexia, dry mouth, abdominal discomfort, gastralgia, constipation or diarrhea, hepatic encephalopathy (against the background of liver failure).

From the side of the central nervous system: asthenia, headache, general weakness, fatigue, lethargy, lethargy, malaise, vertigo, muscle spasm, nervousness, tension, irritability, agitation; anxiety, insomnia, depression, dizziness, drowsiness.

From the senses: conjunctivitis, visual impairment.

From the respiratory system: rhinitis, rarely - cough, pharyngitis, sinusitis.

From the cardiovascular system: orthostatic hypotension, arrhythmia, palpitations, changes in the ECG (hypokalemia).

From the urinary system: nocturia, polyuria, increased frequency of infections.

Allergic reactions: itching, rash, urticaria, hemorrhagic vasculitis.

From the organs of hematopoiesis: thrombocytopenia, leukopenia, agranulocytosis, bone marrow aplasia, hemolytic anemia.

On the part of laboratory indicators: hypercalcemia, hyperuricemia, hypochloremia, hyponatremia, hyperglycemia, hypokalemia, increased urea nitrogen in the blood plasma, hypercreatininemia, glycosuria.

Other: flu-like syndrome, chest pain, back pain, decreased potency and / or libido, rhinorrhea, sweating, weight loss, paresthesia in the limbs, exacerbation of systemic lupus erythematosus, pancreatitis.

Storage conditions

The drug should be stored out of the reach of children, protected from light at a temperature not exceeding 25 ° C.

Shelf life - 5 years. Do not use after the expiration date.

Read more
Product Details

Data sheet

Dosage form
10 mg
Number of tablets
INN Russian
Russian title
No comments

Be the first to write your review !



Create a free account to save loved items.

Sign in

Create a free account to use wishlists.

Sign in